Structure of GSK232

potent, selective CECR2 bromodomain inh.

cell permeable tool compound

from HTS + SBDD on ATAD2, CECR2 model

J. Med. Chem., May 28, 2020

GlaxoSmithKline, Stevenage, UK

GSK232 is a highly selective cell-penetrant inhibitor of the non-BET CECR2 bromodomain with >500-fold selectivity over BET-family bromodomains identified during a campaign to find selective inhibitors of the bromodomain…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.